$LALPATHLAB Financial performance and key operating metrics (consolidated) Operating Revenue for Q1FY27 is Rs. 798 Crs., 19.1% growth YoY (“highest quarterly growth rate achieved in the last four years), Total Income is Rs. 830 Crs., 18.87% growth YoY, Gross Profit is Rs. 530 Crs., 19.12% growth YoY, EBITDA is Rs. 248 Crs., 28.71% growth YoY, EBITDA Margin is 31.03% improved by 232 basis points YoY, PBT Rs. 229 Crs., 26.28% growth YoY, PAT Rs. 171 Crs. 27.24% growth YoY. On QoQ basis Op. Revenue is up by 13.52%, Total Income is up by 14.16%, Gross Profit is up by 13.56%, EBITDA is up by 32.49%, EBITDA Margin also improved by 444 BPS, PBT is up by 42.85% and PAT is also up by 28.97%. Patient volumes: 8.2 million, +8.2% YoY, Sample volumes: 25.9 million, +10.7% YoY. New launches: 116 new tests in the quarter, including 4 “first in India” tests. CGHS/ECHS price revisions are now “flowing through into the system.” Hospitals capacity expansion enabling “stronger clinical partnerships” and “great scope for super specialized testing over time.”

#FundamentalViews#WatchOutFor#StockInNews#EquityResearch#TrendingSectors

914 likes·86 comments